Longevity & Cellular
ARA-290
Research Use OnlyThese products are sold strictly for laboratory and research use only and are not approved for human consumption, diagnosis, or therapeutic treatment. Not for human or veterinary use. These statements have not been evaluated by the Food and Drug Administration, and nothing on this page constitutes medical advice or a health claim.
- Size
- 10mg
Specifications
ARA-290 Technical Profile
OVERVIEW
What Is ARA-290 (Cibinetide) Peptide?
ARA-290 (Cibinetide) is a synthetic undecapeptide engineered from the B-helix region of erythropoietin (EPO). Developed by Araim Pharmaceuticals, ARA-290 was designed to retain the tissue-protective signaling properties of EPO while eliminating its erythropoietic (red blood cell-stimulating) activity. This non-erythropoietic EPO-derived peptide selectively activates the innate repair receptor (IRR), making it a unique research tool for studying tissue protection and repair mechanisms without the hematological confounders associated with EPO itself.
Published research on ARA-290 peptide spans neuroprotection, metabolic neuropathy, sarcoidosis-associated neuropathy, and tissue repair models. The peptide's ability to activate the IRR, a heterodimeric complex of the EPO receptor (EPOR) and the beta common receptor (βcR/CD131), without triggering classical erythropoiesis has made cibinetide a valuable tool in laboratories investigating cytoprotective signaling pathways. ARA-290 research has progressed from preclinical models through multiple clinical research studies.
- 01
IRR-Selective Peptide
11-amino-acid EPO-derived peptide targeting the innate repair receptor without erythropoietic activity
- 02
≥99% HPLC Purity
Every batch verified via high-performance liquid chromatography
- 03
USA Tested & Verified
Third-party analytical testing performed in USA laboratories
RESEARCH
ARA-290 Mechanism of Action in Research
The ARA-290 mechanism of action is distinct from classical erythropoietin signaling. While EPO activates homodimeric EPOR to stimulate erythropoiesis, ARA-290 selectively engages the innate repair receptor (IRR), triggering tissue-protective and anti-inflammatory signaling cascades. Published research has elucidated multiple downstream pathways activated by ARA-290's IRR engagement, providing insight into non-erythropoietic cytoprotective mechanisms.
Innate Repair Receptor (IRR) Activation
ARA-290 binds to the innate repair receptor, a heterodimer composed of EPOR and βcR (CD131). Research by Brines et al. (2008) demonstrated that this receptor complex is expressed on a wide variety of cell types including neurons, endothelial cells, and immune cells. Upon ARA-290 binding, the IRR activates JAK2/STAT5 signaling, PI3K/Akt pathways, and NF-κB modulation, collectively producing cytoprotective and anti-inflammatory effects in research models. Critically, ARA-290's affinity for the IRR is insufficient to activate the homodimeric EPOR, eliminating erythropoietic activity.
Anti-Inflammatory Signaling Pathways
Studies indicate that ARA-290 modulates inflammatory signaling through multiple mechanisms. Research published by Brines & Cerami (2012) in Molecular Medicine demonstrated that ARA-290 downregulates pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β while upregulating anti-inflammatory mediators. In preclinical models, ARA-290 has been observed to shift macrophage polarization from M1 (pro-inflammatory) toward M2 (anti-inflammatory/reparative) phenotypes, suggesting a role in resolution of inflammation and tissue repair signaling.
Neuroprotective Research Applications
ARA-290 research has demonstrated notable effects in neuroprotection models. Brines et al. (2008) published findings showing that ARA-290 activated neuroprotective pathways in dorsal root ganglia neurons. Subsequent clinical research by Heij et al. (2012) investigated ARA-290 in sarcoidosis-associated small fiber neuropathy models, documenting improvements in nerve fiber density measures, further establishing the peptide's relevance to neuroscience research. ---
COMPARISON
ARA-290 vs EPO: Research Compound Comparison
ARA-290
ARA-290 (Cibinetide) and erythropoietin (EPO) share a structural origin but differ fundamentally in receptor targeting, biological activity, and research applications. Understanding these differences is critical for researchers working with cytoprotective and erythropoietic signaling pathways.
EPO
ARA-290's selective IRR targeting without erythropoietic activity represents a significant advancement for researchers studying tissue-protective EPO signaling without hematological confounders. VivePeptides offers research grade ARA-290 for sale at ≥99% purity from our USA-based facility.
| Feature | ARA-290 (Cibinetide) | EPO (Erythropoietin) |
|---|---|---|
| Type | Synthetic undecapeptide | Glycoprotein hormone (165 aa) |
| Molecular Weight | 1257.43 Da | ~30,400 Da |
| CAS Number | 1208243-50-8 | 11096-26-7 |
| Target Receptor | Innate Repair Receptor (EPOR/βcR) | Homodimeric EPOR |
| Erythropoietic Activity | None | Primary function |
| Primary Research Focus | Neuroprotection, tissue repair, anti-inflammation | Erythropoiesis, red blood cell production |
| Safety Profile in Research | No hematological confounders | Thrombotic risk at high doses |
| Administration Route (Research) | Subcutaneous, intravenous | Subcutaneous, intravenous |
| Research Stage | Phase 2 clinical studies completed | FDA-approved therapeutic |
RESEARCH STUDIES
ARA-290 Research Applications & Published Studies
ARA-290 research includes both preclinical and clinical investigations, with published findings spanning multiple therapeutic research areas. The following areas represent the most actively investigated applications of ARA-290 peptide. All references are to research contexts only.
Neuropathy and Neuroprotection Research
The most extensively studied application of ARA-290 involves neuroprotection and neuropathy models. Brines et al. (2008) published foundational work in the Proceedings of the National Academy of Sciences demonstrating ARA-290's neuroprotective properties via IRR activation. Heij et al. (2012) subsequently published clinical research findings in Molecular Medicine showing that ARA-290 improved corneal nerve fiber measures in patients with sarcoidosis-associated small fiber neuropathy, representing a significant translational milestone.
Metabolic Neuropathy Research
Research has explored ARA-290 in metabolic neuropathy models. Brines et al. (2014) published findings in BMC Neurology from a randomized controlled study investigating ARA-290 in type 2 diabetes-associated neuropathy. The study documented effects on small nerve fiber measures and neuropathic symptoms, contributing to the understanding of IRR-mediated neuroprotection in metabolic disease research contexts.
Tissue Protection and Repair Studies
Preclinical ARA-290 research has examined the peptide's tissue-protective properties across multiple organ systems. Collino et al. (2013) published studies demonstrating ARA-290's effects in renal ischemia-reperfusion models. Additional research by Ahmet et al. (2011) investigated ARA-290 in cardiac injury models, observing cytoprotective effects consistent with IRR-mediated anti-apoptotic signaling, expanding the scope of ARA-290 research to cardiovascular biology.
QUALITY ASSURANCE
Quality & Testing Standards
VivePeptides maintains rigorous quality control for every batch of ARA-290 peptide. Our commitment to research-grade purity ensures that laboratories receive consistent, reliable compounds for their investigations.
HPLC & Mass Spectrometry
Every batch of ARA-290 undergoes high-performance liquid chromatography (HPLC) and mass spectrometry analysis to confirm identity, purity, and molecular weight.
Third-Party Verified
All VivePeptides ARA-290 is independently verified through third-party analytical laboratories based in the USA. Testing documentation is available for every lot.
≥99% Purity Standard
Our ARA-290 consistently meets or exceeds ≥99% purity as determined by HPLC analysis, ensuring research-grade quality for laboratory applications.
FAQ
Frequently Asked Questions About ARA-290
What is ARA-290 used for in research?
What purity is VivePeptides ARA-290?
How should ARA-290 be stored?
What is the difference between ARA-290 and EPO?
Is VivePeptides ARA-290 third-party tested?
BPC-157
Research grade gastric pentadecapeptide for tissue biology studies
TB-500
MOTS-c
Thymosin Beta-4 fragment for tissue repair and cell migration research
Mitochondrial-derived peptide for metabolic research
Selank
Nootropic peptide for neuropeptide research
Explore More Research Peptides
All Peptides → · BPC-157 · TB-500 · Semax · NAD+ · GHK-Cu · BAC Water
Add To Research Cart
ARA-290
99%+ purity · USA lab tested · secure shipping
You May Also Research
Related Compounds
These products are sold strictly for laboratory and research use only and are not approved for human consumption, diagnosis, or therapeutic treatment. Not for human or veterinary use. These statements have not been evaluated by the Food and Drug Administration, and nothing on this page constitutes medical advice or a health claim.